Cortistatin
What the Research Actually Shows
Human: 0 studies, 1 groups · Animal: 2 · In Vitro: 0
The brain's own deep-sleep peptide—sharing 11 of 14 amino acids with somatostatin but doing something somatostatin cannot, discovered in 1996 by the co-discoverer of orexin, and untouched by clinical development
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Cortistatin is a peptide your brain makes when it is time for deep sleep. When scientists injected it into rat brains, it increased the slow delta waves that define the deepest stage of sleep—the stage your body uses for tissue repair, memory consolidation, and immune function. Cortistatin looks almost identical to somatostatin—they share 11 of 14 amino acids—but somatostatin does not promote deep sleep. Cortistatin does. It was discovered in 1996 by Luis de Lecea, who co-discovered orexin two years later. No drug company has developed a cortistatin-based therapy. No human has been given cortistatin in a clinical trial. The sleep biology is interesting. The clinical evidence is nonexistent.
Cortistatin occupies an unusual niche in the neuropeptide landscape: it is a peptide that almost no one outside sleep neuroscience has heard of, discovered by one of the most successful neuropeptide hunters in modern science, with a mechanism that directly addresses one of the most important questions in sleep medicine—how the brain generates and maintains deep slow-wave sleep.
The molecule itself is a 14-amino-acid peptide (CST-14; a 17-amino-acid form, CST-17, also exists) produced exclusively by GABAergic interneurons in the cerebral cortex and hippocampus. It shares 11 of its 14 amino acids with somatostatin-14—the growth-hormone-inhibiting peptide—but is encoded by a separate gene (CORT on chromosome 1) and has at least one function somatostatin does not: promotion of cortical slow oscillations and slow-wave sleep. When injected into the brain ventricles of rats, cortistatin increases EEG delta power (1–4 Hz)—the electrical signature of deep NREM sleep—and increases total time spent in slow-wave sleep (de Lecea et al., 1996; PMID 8622767).
The discoverer, Luis de Lecea, named it for what it does: "cortistatin" = cortical activity depression in somatostatin-like fashion. Two years later, de Lecea co-discovered hypocretin/orexin—the wakefulness peptide that generated three FDA-approved drugs and the definitive mechanism of narcolepsy. Cortistatin has not had that trajectory. No pharmaceutical company has developed it. No clinical trial has tested it. This article examines why the biology is compelling, why the structural similarity to somatostatin creates pharmacological challenges, and what cortistatin tells us about the mechanisms of deep sleep.
In This Article
Quick Facts: Cortistatin at a Glance
Type
Endogenous neuropeptide, exists as CST-14 (14 amino acids) and CST-17 (17 amino acids, N-terminal extension)
Also Known As
CST, Cortistatin-14, CST-14, CST-17, preprocortistatin
Generic Name
None. No pharmaceutical product exists.
Route
ICV injection (intracerebroventricular—directly into brain ventricles) in animal research. No peripheral, oral, intranasal, or injectable protocol established. The peptide must reach the cerebral cortex to exert sleep effects.
Molecular Weight
CST-14: ~1,630 Da. CST-17: ~2,030 Da.
Peptide Sequence
CST-14: Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys. Shares 11 of 14 amino acids with somatostatin-14 (SST-14). The three differing positions give cortistatin its unique sleep-promoting properties.
Endogenous Origin
Yes. Produced exclusively by a subset of GABAergic interneurons in the cerebral cortex and hippocampus—not in hypothalamus, not in pancreas, not in gut (unlike somatostatin, which is produced in many tissues). Encoded by the CORT gene on chromosome 1, separate from the somatostatin gene.
Primary Molecular Function
Depresses cortical excitability by antagonizing the excitatory effects of acetylcholine on cortical neurons. Promotes slow-wave (delta) oscillations. Also activates ion currents not responsive to somatostatin. Binds MrgX2 receptor (unique to cortistatin) and ghrelin receptor (GHS-R1a) in addition to somatostatin receptors sst1–5.
Active Fragment
CST-14 is the primary active form studied in sleep experiments. The three amino acids that distinguish CST-14 from SST-14 are necessary for sleep-promoting activity—somatostatin does not produce the same effect.
Brand Name
None. No cortistatin therapeutic has been developed.
Related Compound Relationship
Shares 11/14 amino acids with somatostatin-14 but encoded by a separate gene with distinct expression pattern and function. Discovered by the same scientist (de Lecea) who co-discovered orexin (also in Cluster J). Pharmacologically cross-reactive with somatostatin receptors, which complicates drug development.
Clinical Programs
None. No pharmaceutical or academic clinical development program exists for cortistatin. No IND filed. No clinical trial registered.
WADA Status
Not on the Prohibited List
Community Interest
Essentially none. Cortistatin is not available from consumer peptide vendors. It is discussed in academic sleep neuroscience but has no presence in biohacking, bodybuilding, or peptide self-experimentation communities.
FDA Status
Not approved. Not in development. Not available as a pharmaceutical product.
Half-Life
Unknown in humans. In animal models, cortistatin is rapidly cleared (minutes). The somatostatin receptor cross-reactivity suggests similar enzymatic degradation pathways.
Evidence Tier
4 Preclinical Only
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Cortistatin?
Pronunciation: KOR-tih-STAT-in
Deep sleep is not a passive state. The large, slow electrical waves that define stage 3 NREM sleep—delta oscillations, 1–4 Hz—are actively generated by coordinated firing of cortical neurons. These slow waves are not noise. They are the mechanism by which the brain consolidates memories, clears metabolic waste through the glymphatic system, and coordinates tissue repair via growth hormone release. Anything that reliably deepens slow-wave sleep has enormous clinical potential—and cortistatin is the only neuropeptide specifically demonstrated to do exactly that.
Cortistatin is a 14-amino-acid peptide produced by a subset of inhibitory interneurons in the cerebral cortex and hippocampus. It was discovered in 1996 by Luis de Lecea—a neuroscientist who would go on to co-discover orexin/hypocretin two years later—through a subtractive cloning strategy designed to identify genes expressed specifically in the cortex (de Lecea et al., 1996; PMID 8622767). The name combines "cortical" (where it is expressed), "statin" (because it shares structural similarity with somatostatin), and an implied function: it depresses cortical activity, quieting the excitatory neural chatter that characterizes wakefulness and allowing slow-wave oscillations to emerge.
The structural overlap with somatostatin is striking—11 of 14 amino acids are identical—but the functional divergence is equally striking. Somatostatin inhibits growth hormone release, slows gut motility, and suppresses insulin and glucagon secretion. It does not promote slow-wave sleep. Cortistatin promotes slow-wave sleep. The three amino acid differences between them—and cortistatin's unique receptor interactions (MrgX2, GHS-R1a)—account for this divergence.
PLAIN ENGLISH
Cortistatin is a small peptide made by a specific type of brain cell in your cerebral cortex. Its job appears to be helping your brain shift into deep sleep—the kind of sleep where brain waves slow way down and your body does its most important repair work. It looks almost identical to another peptide called somatostatin, but somatostatin does not promote deep sleep. Cortistatin does. It was found by the same scientist who discovered the wakefulness peptide orexin, but unlike orexin, no one has ever tried to develop cortistatin into a drug.
Origins and Discovery
Luis de Lecea was looking for cortex-specific genes. Using subtractive hybridization—a technique that identifies mRNAs enriched in one tissue compared to another—he screened rat cerebral cortex against whole brain, searching for genes expressed uniquely in the cortical sheet. One of the hits encoded a small prepropeptide whose processed form was a 14-amino-acid peptide bearing unmistakable similarity to somatostatin-14. But the gene was different (mapped to a separate chromosomal locus), the expression pattern was different (exclusively cortical and hippocampal interneurons, not the broad distribution of somatostatin), and when the peptide was injected into rat brain ventricles, it did something somatostatin did not: it enhanced slow-wave sleep.
De Lecea named it cortistatin and published the discovery in 1996 (PMID 8622767). The follow-up paper in 1997 (PMID 9221784) mapped its expression to a subset of GABAergic interneurons in layers II–VI of the cortex and the hippocampus—a restricted distribution that made biological sense for a peptide involved in cortical state regulation.
The timing is remarkable in retrospect. In 1996, de Lecea discovered cortistatin—the deep-sleep peptide. In 1998, working with Tom Kilduff, he co-discovered hypocretin (later named orexin by a competing group)—the wakefulness peptide. The same scientist found both sides of the sleep-wake coin within two years. Orexin generated three FDA-approved drugs and redefined sleep medicine. Cortistatin generated a handful of papers and no clinical development whatsoever. The disparity is not a reflection of scientific merit—it is a reflection of the economics of drug development and the pharmacological complexity of a peptide that cross-reacts with five somatostatin receptors.
PLAIN ENGLISH
A neuroscientist looking for brain-specific genes in 1996 found a small peptide made only by certain brain cells. When he injected it into rat brains, it deepened their sleep. He named it cortistatin. Two years later, the same scientist co-discovered orexin—the peptide that keeps you awake. Orexin became one of the biggest stories in sleep medicine. Cortistatin has been largely ignored, not because the science is weak, but because developing a drug from a peptide that binds five different somatostatin receptors is pharmacologically complicated.
Mechanism of Action
Cortical Activity Depression
Cortistatin's sleep-promoting mechanism operates at the cortical level—it acts directly on the neural circuits that generate the electrical patterns of wakefulness and sleep:
Acetylcholine antagonism: During wakefulness, cholinergic projections from the basal forebrain (nucleus basalis of Meynert) release acetylcholine onto cortical neurons, maintaining the fast, desynchronized electrical activity that characterizes alert consciousness. Cortistatin opposes this excitatory cholinergic input—not by blocking acetylcholine receptors directly, but by activating inhibitory signaling cascades on the same cortical neurons that receive cholinergic input. The net effect: cortical excitability drops, and the slow, synchronized oscillations of deep sleep emerge.
Delta wave enhancement: When administered into the cerebral ventricles of rats, cortistatin increases EEG power in the delta band (1–4 Hz) and increases total time spent in slow-wave sleep. The delta enhancement is specific to cortistatin—somatostatin, despite binding the same receptor family, does not produce this effect. This dissociation is the strongest evidence that cortistatin's sleep-promoting actions involve receptor interactions or signaling pathways that somatostatin does not engage.
Unique Receptor Pharmacology
Cortistatin binds all five somatostatin receptors (sst1–5) with affinities comparable to somatostatin itself. But it also binds two receptors that somatostatin does not:
MrgX2 (Mas-related G protein-coupled receptor X2): This receptor is unique to cortistatin—somatostatin has no affinity for it. MrgX2 is expressed on mast cells, nociceptive neurons, and cortical neurons. Its role in cortistatin's sleep-promoting effects is under investigation but may explain why cortistatin and somatostatin diverge functionally despite sharing five receptor targets.
GHS-R1a (ghrelin receptor): Cortistatin binds the ghrelin receptor, which is primarily known for appetite stimulation and growth hormone release. This cross-reactivity could have metabolic consequences if cortistatin were administered systemically.
Circadian Expression and Homeostatic Regulation
Cortistatin mRNA expression in the cortex follows a circadian pattern—higher during the rest phase (when sleep occurs) and lower during the active phase. Furthermore, cortistatin mRNA is significantly upregulated after sleep deprivation, consistent with a homeostatic sleep factor: the longer you stay awake, the more cortistatin your cortical interneurons produce, increasing the pressure to enter deep sleep. This expression pattern parallels adenosine accumulation—the other major homeostatic sleep signal—but operates through a completely different mechanism.
Why Not Somatostatin?
The question is obvious: if cortistatin and somatostatin share 11 of 14 amino acids and bind the same five receptors, why does cortistatin promote sleep and somatostatin does not? The answer appears to involve three factors:
1. The three divergent amino acids alter the peptide's conformational dynamics, potentially changing how it interacts with shared receptors (biased agonism—same receptor, different downstream signaling) 2. MrgX2 engagement is cortistatin-specific and may be necessary for the sleep-promoting effect 3. Expression pattern: Cortistatin is released locally in the cortex by interneurons, while somatostatin is released broadly from the hypothalamus, gut, and pancreas. The local cortical delivery may be essential—the right peptide in the right place.
PLAIN ENGLISH
Cortistatin works by quieting down the brain's outer layer—the cortex—so that slow, deep-sleep brain waves can take over. During wakefulness, a chemical called acetylcholine keeps cortical neurons firing fast. Cortistatin opposes that excitation, allowing the slow rhythms of deep sleep to emerge. Your brain makes more cortistatin the longer you have been awake—the same way sleep pressure builds. The reason cortistatin works and its near-twin somatostatin does not appears to involve three amino acid differences and at least one receptor that only cortistatin can activate.
Key Research Areas and Studies
Discovery and Sleep Promotion (de Lecea et al., 1996)
Study: A cortical neuropeptide with neuronal depressing and sleep-modulating properties. PMID: 8622767 Design: ICV injection of cortistatin-14 in rats with EEG monitoring. Key findings: CST-14 significantly increased cortical delta power (1–4 Hz) and time spent in slow-wave sleep. Reduced REM sleep. Decreased locomotor activity. Effects were distinct from those of somatostatin administered via the same route. Significance: Established cortistatin as a sleep-modulating neuropeptide with specific slow-wave-enhancing properties not shared by its structural relative somatostatin.
Cortistatin Expression Mapping (de Lecea et al., 1997)
Study: Cortistatin is expressed in a distinct subset of cortical interneurons. PMID: 9221784 Design: In situ hybridization mapping in rat brain. Key findings: Cortistatin mRNA exclusively expressed in GABAergic interneurons of the cerebral cortex (layers II–VI) and hippocampus. Not detected in hypothalamus, thalamus, or brainstem. Distinct from somatostatin expression, which is widespread. Circadian variation in expression level. Significance: Established that cortistatin and somatostatin, despite sequence similarity, are produced by different cell populations in different brain regions—supporting functional divergence.
Cortistatin as Homeostatic Sleep Factor
Multiple publications from de Lecea's group have demonstrated that cortistatin mRNA increases after sleep deprivation in rodents. This homeostatic upregulation—more cortistatin when sleep need is high—is a defining characteristic of a sleep factor, analogous to adenosine accumulation. The circadian expression pattern (higher during the rest phase) further supports a physiological role in sleep promotion rather than a pharmacological artifact.
Cortistatin Anti-Inflammatory Properties
Separate from its sleep role, cortistatin has been studied for anti-inflammatory effects. It modulates macrophage function, reduces inflammatory cytokine production, and has shown efficacy in animal models of sepsis and inflammatory bowel disease. These effects are mediated primarily through somatostatin receptors (particularly sst2) and are shared to some extent with somatostatin analogs (octreotide, lanreotide). The anti-inflammatory profile may be relevant to cortistatin's sleep-promoting role, given the bidirectional relationship between sleep and immune function.
PLAIN ENGLISH
The original 1996 study injected cortistatin directly into rat brains and showed it deepened sleep—more delta waves, more time in slow-wave sleep. Follow-up studies showed that cortistatin is made by specific brain cells only in the cortex and hippocampus and that its production increases when animals have been kept awake longer—exactly what you would expect from a natural sleep-promoting molecule. Some studies also found anti-inflammatory properties, which fits because deep sleep and immune function are closely connected.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “Cortistatin promotes deep sleep” | ICV cortistatin-14 in rats increases delta power and time in SWS (de Lecea et al., 1996, PMID 8622767). Consistent with homeostatic sleep factor properties. Animal data only. | Preclinical Only |
| “Cortistatin is different from somatostatin” | Same receptor family but unique expression pattern (cortex only), unique receptor engagement (MrgX2, GHS-R1a), unique function (sleep promotion), and encoded by a separate gene. Structurally similar, functionally distinct. | Supported |
| “Cortistatin can treat insomnia” | No human study has tested cortistatin for insomnia or any indication. The peptide requires ICV delivery to the brain in animal models. No drug development program exists. | Unsupported |
| “Cortistatin is a homeostatic sleep factor” | mRNA upregulated after sleep deprivation, circadian expression pattern, SWS promotion. Consistent with homeostatic sleep factor definition. All data from rodents. | Preclinical Only |
| “Cortistatin has anti-inflammatory effects” | Animal models show macrophage modulation and cytokine reduction. Effects mediated through somatostatin receptors. No human anti-inflammatory data specific to cortistatin. | Preclinical Only |
| “Cortistatin could replace sleep medications” | Entirely speculative. No formulation, delivery system, or safety data exists. Cross-reactivity with somatostatin receptors would produce off-target endocrine effects. | Unsupported |
| “Cortistatin explains why deep sleep declines with age” | Age-related decline in cortistatin production has not been documented. The hypothesis is biologically plausible but untested. SWS decline with aging involves multiple mechanisms. | Unsupported |
| “Cortistatin binds the ghrelin receptor” | Yes—cortistatin binds GHS-R1a (ghrelin receptor). Confirmed in binding studies. Functional significance for sleep is unclear. May explain some metabolic effects. | Supported |
| “The three amino acid differences explain sleep specificity” | Plausible but not proven. The divergent amino acids may enable MrgX2 binding and biased agonism at shared sst receptors. The mechanism of functional divergence from somatostatin is under investigation, not resolved. | Mixed Evidence |
| “Cortistatin supplements could improve sleep” | Cortistatin is not available as a supplement. It requires delivery to the brain (ICV in animal models). Oral or injectable cortistatin would not reach the cortex in meaningful concentrations and would activate peripheral somatostatin receptors. | Unsupported |
| “De Lecea discovered both sides of sleep-wake regulation” | Factually accurate. De Lecea discovered cortistatin (SWS promoter, 1996) and co-discovered hypocretin/orexin (wake promoter, 1998). Both findings are published and verified. | Supported |
| “Cortistatin is more important than somatostatin for sleep” | Cortistatin promotes SWS; somatostatin does not produce the same effect. For sleep specifically, cortistatin appears functionally unique. "More important" is a judgment, but the evidence supports cortistatin's sleep role. | Preclinical Only |
The Human Evidence Landscape
There is no human evidence landscape for cortistatin. No clinical trial. No human dosing study. No pharmacokinetic data in humans. No safety profile in humans. The entire evidence base consists of rodent studies performed primarily by the discoverer's laboratory and a handful of collaborating groups.
This is not inherently a criticism. Many important neuropeptides have limited human data. But it means that every claim about cortistatin's potential is extrapolated from animal models, and the translational gap—from rat brain ICV injection to human sleep therapy—is enormous. The challenges include:
Delivery: Cortistatin's sleep effects have been demonstrated only via ICV injection—directly into the brain's ventricular system. There is no evidence that peripheral (subcutaneous, IV, or intranasal) administration of cortistatin produces CNS effects. The peptide is a 14-amino-acid fragment that would face enzymatic degradation in blood and limited blood-brain barrier penetration.
Receptor selectivity: Cortistatin binds all five somatostatin receptors. Systemic cortistatin would produce somatostatin-like effects—growth hormone suppression, gastrointestinal slowing, insulin/glucagon modulation—alongside any sleep-promoting action. This creates a challenging therapeutic index: the dose that promotes sleep might also suppress growth hormone release, which is counterproductive since GH release is itself a benefit of deep sleep.
Replication: The core sleep findings come from a relatively small number of publications, predominantly from the discovering laboratory. Independent replication by other groups, while present (Spier & de Lecea, 2000), is limited. The field has not coalesced around cortistatin as a drug target the way it did around orexin.
PLAIN ENGLISH
No one has tested cortistatin in humans—not for sleep, not for anything. All the evidence comes from injecting it directly into rat brains. The challenges of turning this into a human treatment are significant: the peptide needs to reach the brain, it binds the same receptors as somatostatin (which would cause unwanted hormonal effects), and the core findings have not been widely replicated outside the discovering lab. The biology is interesting. The translational path does not exist.
Safety, Risks, and Limitations
No Human Safety Data
Cortistatin has never been administered to a human subject. There is no safety profile, no adverse event record, and no toxicology data beyond standard peptide screening.
Theoretical Risks from Receptor Cross-Reactivity
Somatostatin receptor activation (sst1–5): Systemic cortistatin would be expected to produce somatostatin-like effects including growth hormone suppression, reduced insulin and glucagon secretion, slowed gastrointestinal motility, and reduced bile flow. These are well-characterized effects of somatostatin analogs (octreotide, lanreotide) and would be dose-limiting for any systemic cortistatin formulation.
Ghrelin receptor activation (GHS-R1a): Could stimulate appetite, increase growth hormone release (opposing the sst-mediated GH suppression in a complex pharmacological interaction), and affect reward circuitry.
MrgX2 activation: MrgX2 on mast cells can trigger degranulation (histamine release, allergic-type reactions). Whether cortistatin at physiological or pharmacological concentrations would produce clinically significant mast cell activation is unknown.
Delivery Barrier
The ICV delivery requirement in animal studies is a fundamental limitation. Intracerebroventricular injection is a neurosurgical procedure—not a practical therapeutic route. Without evidence that peripheral delivery achieves CNS concentrations sufficient for sleep modulation, cortistatin cannot progress toward clinical application.
PLAIN ENGLISH
Since no human has ever received cortistatin, we do not know what the side effects are. The main concern is that cortistatin would activate the same receptors as somatostatin—causing hormone changes, gut slowing, and blood sugar effects—alongside any sleep benefit. There is also a risk of allergic-type reactions through a receptor on mast cells. And the fundamental problem remains: to affect sleep, cortistatin needs to reach the cortex, and no one has shown that it can get there without being injected directly into the brain.
Legal and Regulatory Status
Cortistatin has no regulatory status as a pharmaceutical. It is not FDA-approved, not in clinical development, and not classified as a controlled substance. Research-grade cortistatin-14 is available from laboratory peptide suppliers (Bachem, Tocris, Phoenix Pharmaceuticals) for institutional research use.
Cortistatin is not available from consumer peptide vendors and is not marketed as a supplement, nootropic, or sleep aid. No regulatory pathway has been initiated.
WADA does not list cortistatin on its Prohibited List.
Research Protocols and Formulation Considerations
Animal Research Protocol (Reference)
| Parameter | Detail |
|---|---|
| Compound | Cortistatin-14 (synthetic) |
| Route | Intracerebroventricular (ICV) via surgically implanted cannula |
| Dose | 0.1–1.0 nmol ICV in rats |
| Measurement | EEG power spectral analysis (delta 1–4 Hz), sleep-wake state scoring |
| Key finding | Dose-dependent increase in delta power and SWS time |
Storage
Research-grade cortistatin: lyophilized powder at −20°C (−4°F). Reconstituted solutions: 2–8°C (36–46°F), use within 24 hours. Susceptible to enzymatic degradation similar to somatostatin.
Dosing in Published Research
The following table summarizes dosing protocols for Cortistatin as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Published Research Dosing
| Parameter | Detail |
|---|---|
| Route | ICV only (intracerebroventricular) in animal models |
| Dose range | 0.1–1.0 nmol CST-14 in rats |
| Human dose | Does not exist — no human study has been conducted |
| Peripheral dose | Not established — no evidence peripheral administration produces CNS effects |
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Cortistatin has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Why This Section Is Nearly Empty
Cortistatin is not part of any self-experimentation community. It is not sold by peptide vendors, not discussed in biohacking forums for practical use, and requires direct brain injection to produce its known sleep effects. There is no consumer protocol, no dosing guide, and no anecdotal experience base. The entire knowledge of cortistatin exists within academic sleep neuroscience research.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Cortistatin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Cortistatin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Cortistatin Compares
Cortistatin belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Sleep, Stress & Recovery cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Primary Application | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Neuropeptide Y | Neuropeptide (36 aa) | Tier 2 — Clinical Trials | Eyes Open | Y1 receptor anxiolysis, CRH antagonism, HPA axis modulation | Stress resilience, PTSD, anxiety | Phase Ib RCT (intranasal, PTSD) + RCT (MDD) — ~54 patients total | Not approved | Not prohibited | Small early-phase trials; intranasal BBB penetration uncertain |
| Desmopressin | Synthetic vasopressin analog (9 aa, cyclic) | Tier 1 — Approved Drug | Strong Foundation | V2 receptor agonism → antidiuresis → reduced nocturnal urine volume | Nocturnal enuresis, nocturia, central DI | Cochrane review (47 RCTs, N=3,448) + Phase III nocturia (N=757) | Approved (multiple formulations, 1978+) | Not prohibited | Hyponatremia risk; nasal spray withdrawn for enuresis (2007) |
| Corticotropin-Releasing Hormone | Neuropeptide (41 aa) | Tier 4 — Preclinical (therapeutic) | Eyes Open | HPA axis master switch — CRH-R1 activation → ACTH → cortisol | Understanding stress biology; CRH-R1 antagonists for depression (failed) | Biomarker studies (elevated CSF CRH in depression); CRH-R1 antagonist trials failed | Diagnostic only (Acthrel for Cushing's differentiation) | Not prohibited | CRH-R1 antagonists failed in depression trials despite strong mechanistic rationale |
| Orexin | Neuropeptide pair (OxA 33 aa + OxB 28 aa) | Tier 1 — Approved Drug | Strong Foundation | OX1R/OX2R wake promotion; loss → narcolepsy | Insomnia (via DORAs); narcolepsy diagnosis/treatment | 3 Phase III DORA trials (N=4,945 total); CSF orexin diagnostic for narcolepsy | 3 DORAs approved (suvorexant 2014, lemborexant 2019, daridorexant 2022) | Not prohibited (DORAs may be relevant) | DORAs are small molecules not peptides; orexin agonists for narcolepsy still in development |
| Cortistatin | Neuropeptide (14–17 aa, somatostatin-related) | Tier 4 — Preclinical Only | Eyes Open | Cortical activity depression → slow-wave sleep induction; ACh antagonism | Deep sleep promotion (theoretical) | None | Not approved | Not prohibited | No human data; single research group; somatostatin receptor cross-reactivity |
| Galanin | Neuropeptide (29 aa) | Tier 3 — Limited Human Data | Eyes Open | VLPO sleep-switch activation; LC noradrenergic inhibition | Sleep initiation; potential antidepressant | 1 IV study in healthy men: increased REM, preliminary antidepressant signal | Not approved | Not prohibited | Single small human study; 3 receptor subtypes with opposing effects complicate targeting |
| PACAP | Neuropeptide (27–38 aa, VIP family) | Tier 2 — Clinical Trials | Eyes Open | PAC1/VPAC receptor activation → stress amplification + migraine | Migraine prevention (via anti-PAC1 antibody); PTSD genetics | Phase 2 anti-PAC1 antibody (migraine, positive); PTSD genetic association | Not approved (anti-PAC1 Lu AG09222 Phase 2b ongoing) | Not prohibited | Therapeutic = blocking PACAP not administering it; stress/sleep applications undeveloped |
| Melanin-Concentrating Hormone | Neuropeptide (19 aa) | Tier 4 — Preclinical Only | Eyes Open | MCH neuron activation → selective REM sleep promotion | REM sleep regulation; narcolepsy (MCHR1 antagonism) | None clinical | Not approved; HBS-102 IND stage (narcolepsy) | Not prohibited | No human clinical data; obesity MCHR1 programs failed; narcolepsy IND not advanced |
| Cosyntropin | Synthetic ACTH fragment (24 aa) | Tier 1 — Approved Drug | Strong Foundation | MC2R activation → adrenal cortisol production | Adrenal insufficiency diagnosis (ACTH stimulation test) | Millions of diagnostic tests performed worldwide since 1970 | Approved diagnostic (Cortrosyn, 1970). Synacthen Depot therapeutic (EU/UK). | Prohibited (S2 — ACTH analogs) | US diagnostic only; therapeutic use primarily outside US |
Frequently Asked Questions
What is cortistatin?
Cortistatin is a 14-amino-acid neuropeptide produced by inhibitory neurons in the cerebral cortex and hippocampus. It is the only neuropeptide specifically shown to deepen slow-wave sleep (the deepest stage of NREM sleep) in animal models. It shares 11 of 14 amino acids with somatostatin but has distinct functions, including sleep promotion.
How is cortistatin different from somatostatin?
Despite sharing 11 of 14 amino acids, cortistatin and somatostatin are produced by different cells, expressed in different brain regions, encoded by different genes, and have different functions. Cortistatin promotes deep slow-wave sleep; somatostatin does not. Cortistatin binds two receptors (MrgX2, ghrelin receptor) that somatostatin cannot. The three amino acid differences account for these functional divergences.
Can cortistatin improve my sleep?
Not currently. Cortistatin's sleep-promoting effects have been demonstrated only in rats receiving direct brain injection. No human study exists. No oral, injectable, or nasal cortistatin formulation has been developed. The peptide is not available as a consumer product.
Who discovered cortistatin?
Luis de Lecea discovered cortistatin in 1996 while searching for genes expressed specifically in the cerebral cortex. Two years later, de Lecea co-discovered hypocretin (orexin)—the wakefulness peptide that led to three FDA-approved insomnia drugs. Cortistatin and orexin represent opposite sides of the sleep-wake equation, both found by the same scientist.
Why hasn't cortistatin been developed into a drug?
Three main barriers. First, it can only reach the brain via direct injection in animal studies—no peripheral delivery method works. Second, it binds five somatostatin receptors, meaning a cortistatin drug would also suppress growth hormone, slow the gut, and affect blood sugar. Third, the field has not generated sufficient independent replication to attract pharmaceutical investment.
What are delta waves and why do they matter?
Delta waves are the slow, high-amplitude brain waves (1–4 Hz) that define stage 3 NREM sleep—the deepest sleep stage. During delta-dominant sleep, the brain consolidates memories, the glymphatic system clears metabolic waste (including amyloid-beta linked to Alzheimer's), and growth hormone release peaks. Deep sleep declines significantly with age, and this decline is linked to cognitive deterioration.
Is cortistatin a sleep hormone?
It functions more like a local cortical sleep modulator than a systemic hormone. Unlike melatonin (released into the bloodstream by the pineal gland), cortistatin is released locally by cortical interneurons and acts on nearby neurons to promote the slow oscillations of deep sleep. It is a paracrine signal, not an endocrine one.
Does cortistatin affect growth hormone?
Probably, but through receptor cross-reactivity rather than primary function. Cortistatin binds somatostatin receptors (sst1–5), which are the same receptors somatostatin uses to inhibit growth hormone release. Cortistatin also binds the ghrelin receptor, which stimulates GH release. The net effect on GH from systemic cortistatin exposure is theoretically complex and has not been characterized.
Could cortistatin explain age-related deep sleep decline?
This is an untested hypothesis. Deep sleep declines progressively after age 30, and the cause involves multiple factors including loss of slow-wave-generating cortical neurons, reduced GABAergic inhibition, and possibly reduced cortistatin production. Whether cortistatin specifically declines with age has not been measured in humans.
Is cortistatin being researched for inflammation?
Yes. Cortistatin has anti-inflammatory properties in animal models—it modulates macrophage function and reduces inflammatory cytokines. This is mediated through somatostatin receptors. Some researchers have proposed cortistatin-based therapies for inflammatory conditions (sepsis, IBD), but this line of research is also entirely preclinical.
How does cortistatin relate to other Cluster J compounds?
Cortistatin is the slow-wave-sleep promoter in a cluster that includes the wakefulness peptide (orexin), the stress-response initiator (CRH), the stress-response buffer (NPY), and the anti-nocturia drug (desmopressin). It was discovered by the same scientist who found orexin. Together, they illustrate how the brain uses different neuropeptides to control different aspects of sleep and wakefulness.
Are there cortistatin-based sleep supplements?
No. Cortistatin is not available as a supplement, sleep aid, or consumer product. It is a research-grade peptide available only from laboratory suppliers for institutional use. Any product claiming to contain cortistatin for sleep improvement would have no evidence basis and would likely not deliver the peptide to the brain.
Summary of Key Findings
Cortistatin is the peptide equivalent of an unrealized scientific promise. Discovered in 1996 by Luis de Lecea—who would go on to co-discover orexin two years later—cortistatin is the only neuropeptide specifically shown to enhance slow-wave sleep in animal models. When injected into rat brain ventricles, it increases the delta waves that define deep NREM sleep and increases total time in slow-wave sleep. Its expression is circadian and upregulated after sleep deprivation, consistent with a homeostatic sleep factor. These are the properties of a molecule that, in a parallel universe, might have generated a transformative sleep therapy.
In this universe, cortistatin has gone nowhere clinically. The reasons are pharmacological, not scientific. The peptide shares 11 of 14 amino acids with somatostatin and binds all five somatostatin receptors, meaning any systemic cortistatin drug would produce a cascade of unwanted endocrine effects. The sleep-promoting action requires cortical delivery, which has been achieved only by direct brain injection in rodents. And the field has not generated the critical mass of independent replication needed to attract pharmaceutical investment.
For Peptidings readers, cortistatin is best understood as a window into sleep neuroscience rather than a therapeutic candidate. It demonstrates that deep sleep is not passive—it is actively driven by specific peptides released by specific neurons at specific times. It illustrates the gap between discovering a mechanism and developing a medicine. And it reminds us that the neuropeptide landscape includes molecules whose clinical potential remains entirely untapped.
Verdict Recapitulation
Evidence Tier 4 — Preclinical Only. No human data exists. All evidence comes from rodent ICV studies.
Verdict: Eyes Open. The biology is interesting and the discovery story is compelling—the same scientist found both the deep-sleep peptide and the wakefulness peptide. But the translational barriers are formidable, no development path exists, and the somatostatin receptor cross-reactivity makes drug development complicated. Watch the science. Do not expect a product.
For readers considering Cortistatin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Cortistatin
Further Reading and Resources
If you want to go deeper on Cortistatin, the evidence landscape for sleep, stress & recovery peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Sleep, Stress & Recovery Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Cortistatin — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- de Lecea L, et al. A cortical neuropeptide with neuronal depressing and sleep-modulating properties. Nature. 1996;381(6579):242–245 PubMed
- de Lecea L, et al. Cortistatin is expressed in a distinct subset of cortical interneurons. J Neurosci. 1997;17(15):5868–5880 PubMed
- Spier AD, de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Rev. 2000;33(2–3):228–241 PubMed
- de Lecea L. Cortistatin—functions in the central nervous system. Mol Cell Endocrinol. 2008;286(1–2):88–95 PubMed
- Gonzalez-Rey E, et al. Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J Exp Med. 2006;203(3):563–571 PubMed
- Sakurai T, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–585 PubMed
DISCLAIMER
Cortistatin is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 09, 2026. Next scheduled review: October 06, 2026.